KR102977683B1 - 안구 표면 통증의 치료 방법 - Google Patents

안구 표면 통증의 치료 방법

Info

Publication number
KR102977683B1
KR102977683B1 KR1020217028994A KR20217028994A KR102977683B1 KR 102977683 B1 KR102977683 B1 KR 102977683B1 KR 1020217028994 A KR1020217028994 A KR 1020217028994A KR 20217028994 A KR20217028994 A KR 20217028994A KR 102977683 B1 KR102977683 B1 KR 102977683B1
Authority
KR
South Korea
Prior art keywords
compound
pain
delete delete
ocular
corneal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217028994A
Other languages
English (en)
Korean (ko)
Other versions
KR20210129677A (ko
Inventor
퀸투스 메들리
무네토 모기
미쉘라 몬테치-팔머
칼리오피 스타시
Original Assignee
보슈 롬 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보슈 롬 아일랜드 리미티드 filed Critical 보슈 롬 아일랜드 리미티드
Publication of KR20210129677A publication Critical patent/KR20210129677A/ko
Application granted granted Critical
Publication of KR102977683B1 publication Critical patent/KR102977683B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217028994A 2019-02-15 2020-02-13 안구 표면 통증의 치료 방법 Active KR102977683B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15
US62/806,682 2019-02-15
PCT/IB2020/051210 WO2020165838A1 (en) 2019-02-15 2020-02-13 Methods for treating ocular surface pain

Publications (2)

Publication Number Publication Date
KR20210129677A KR20210129677A (ko) 2021-10-28
KR102977683B1 true KR102977683B1 (ko) 2026-06-16

Family

ID=69740423

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028994A Active KR102977683B1 (ko) 2019-02-15 2020-02-13 안구 표면 통증의 치료 방법

Country Status (17)

Country Link
US (4) US20200261456A1 (cg-RX-API-DMAC7.html)
EP (1) EP3923909A1 (cg-RX-API-DMAC7.html)
JP (3) JP7571037B2 (cg-RX-API-DMAC7.html)
KR (1) KR102977683B1 (cg-RX-API-DMAC7.html)
CN (1) CN113453686B (cg-RX-API-DMAC7.html)
AU (2) AU2020222348B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015998A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130038A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002152A1 (cg-RX-API-DMAC7.html)
IL (1) IL284629A (cg-RX-API-DMAC7.html)
JO (1) JOP20210217A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021009702A (cg-RX-API-DMAC7.html)
PH (1) PH12021551968A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202107260VA (cg-RX-API-DMAC7.html)
TW (2) TW202515576A (cg-RX-API-DMAC7.html)
WO (1) WO2020165838A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104593B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
US12459902B2 (en) * 2020-08-06 2025-11-04 Bausch + Lomb Ireland Limited Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
CN119184616A (zh) * 2024-09-03 2024-12-27 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) 一种疼痛等级的测评方法及其评估系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120510A1 (en) * 2004-06-08 2005-12-22 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010084050A2 (en) * 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US20100152209A1 (en) 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP2009521484A (ja) 2005-12-22 2009-06-04 プロレキシーズ ファーマシューティカルズ インコーポレイテッド 3−アリール置換キナゾロンおよびその使用
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
ES2648225T3 (es) 2007-07-18 2017-12-29 Novartis Ag Combinaciones sinérgicas de antagonistas de VR-1 e inhibidores de COX-2
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
WO2009089057A1 (en) 2008-01-09 2009-07-16 Renovis, Ins. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
AU2017330620A1 (en) 2016-09-20 2019-03-28 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑
JP2019532054A (ja) 2016-09-20 2019-11-07 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Trpv4拮抗薬
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
JP2022520410A (ja) 2019-02-15 2022-03-30 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120510A1 (en) * 2004-06-08 2005-12-22 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010084050A2 (en) * 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JP2012515150A (ja) * 2009-01-13 2012-07-05 ノバルティス アーゲー バニロイドアンタゴニストとして有用なキナゾリノン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XP055688098, pp.1-72(2017.04.11.)*

Also Published As

Publication number Publication date
AU2023203716B2 (en) 2025-03-20
MX2025000353A (es) 2025-02-10
US20220193078A1 (en) 2022-06-23
BR112021015998A2 (pt) 2021-10-05
KR20210129677A (ko) 2021-10-28
JP7571037B2 (ja) 2024-10-22
ZA202104593B (en) 2025-03-26
TWI878266B (zh) 2025-04-01
CN113453686B (zh) 2025-04-15
MX2021009702A (es) 2021-09-14
AU2020222348A1 (en) 2021-08-05
US20210275529A1 (en) 2021-09-09
WO2020165838A9 (en) 2021-03-18
JOP20210217A1 (ar) 2023-01-30
US11234982B2 (en) 2022-02-01
JP2022520832A (ja) 2022-04-01
AU2020222348B2 (en) 2023-03-16
TW202515576A (zh) 2025-04-16
CL2021002152A1 (es) 2022-04-18
TW202045179A (zh) 2020-12-16
US20200261456A1 (en) 2020-08-20
IL284629A (en) 2021-08-31
JP2025004186A (ja) 2025-01-14
PH12021551968A1 (en) 2022-05-23
US20240342174A1 (en) 2024-10-17
EP3923909A1 (en) 2021-12-22
WO2020165838A1 (en) 2020-08-20
AU2023203716A1 (en) 2023-07-06
SG11202107260VA (en) 2021-08-30
JP2026097970A (ja) 2026-06-16
CN113453686A (zh) 2021-09-28
CA3130038A1 (en) 2020-08-20

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)